Valuation: Unicycive Therapeutics, Inc.

Market Cap 97.77M 89.05M 82.05M 74.64M 140M 9.05B 147M 999M 397M 4.94B 367M 359M 15.52B P/E 2026 *
-2.79x
P/E 2027 * 3.41x
Enterprise Value 97.77M 89.05M 82.05M 74.64M 140M 9.05B 147M 999M 397M 4.94B 367M 359M 15.52B EV / Sales 2026 *
85x
EV / Sales 2027 * 0.95x
Free-Float
97.84%
Yield 2026 *
-
Yield 2027 * 62.1%
1 day-5.10%
1 week-5.63%
Current month-10.43%
1 month-13.44%
3 months-40.50%
6 months-56.09%
Current year-41.94%
1 week 3.34
Extreme 3.345
3.83
1 month 3.33
Extreme 3.33
4.02
Current year 3.33
Extreme 3.33
8.74
1 year 3.33
Extreme 3.33
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 17/08/2016
Director of Finance/CFO 64 28/02/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 53 17/08/2016
Director/Board Member 58 31/12/2017
Director/Board Member 58 05/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
28/10/26 Free

Director

30,350 0.1090%
14/05/26 Free

Chief Operating Officer

169,500 0.6716%
14/05/26 Free

Executive/Senior Manager

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
-5.10%-5.63%-37.96%-33.27% 97.77M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.75%-1.66%+25.96%+159.16% 40B
Weighted average by Cap. -1.48%-1.85%+31.81%+155.09%

Financials

2026 *2027 *
Net sales 1.15M 1.05M 966K 878K 1.65M 107M 1.73M 11.75M 4.67M 58.19M 4.32M 4.23M 183M 103M 93.53M 86.18M 78.4M 147M 9.51B 155M 1.05B 417M 5.19B 385M 377M 16.3B
Net income -33.36M -30.38M -28M -25.47M -47.78M -3.09B -50.21M -341M -135M -1.69B -125M -123M -5.3B 23.25M 21.18M 19.51M 17.75M 33.3M 2.15B 35M 237M 94.39M 1.18B 87.24M 85.4M 3.69B
Net Debt - -
Projected Income Statement - Annual - Unicycive Therapeutics, Inc.
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
20/11/26 US$3.350 -5.10% 1,362,292
19/11/26 US$3.530 -1.12% 886,066
18/11/26 US$3.570 -3.51% 1,389,327
17/11/26 US$3.700 0.00% 1,120,705
16/11/26 US$3.700 +4.23% 1,239,729
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Unicycive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.350USD
Average target price
26.30USD
Spread / Average Target
+685.07%
  1. Stock Market
  2. Stocks
  3. UNCY Stock